Authors: Ko, YJ Small, EJ Kabbinavar, F Chachoua, A Taneja, S Reese, D DePaoli, A Hannah, A Balk, SP Bubley, GJ

Citation: Yj. Ko et al., A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer, CLIN CANC R, 7(4), 2001, pp. 800-805

Authors: Strawn, LM Kabbinavar, F Schwartz, DP Mann, E Shawver, LK Slamon, DJ Cherrington, JM

Citation: Lm. Strawn et al., Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts, CLIN CANC R, 6(7), 2000, pp. 2931-2940

Authors: Pegram, M Hsu, S Lewis, G Pietras, R Beryt, M Sliwkowski, M Coombs, D Baly, D Kabbinavar, F Slamon, D

Citation: M. Pegram et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, ONCOGENE, 18(13), 1999, pp. 2241-2251

Authors: Cloughesy, TF Black, KL Gobin, YP Farahani, K Nelson, G Villablanca, P Kabbinavar, F Vineula, F Wortel, CH

Citation: Tf. Cloughesy et al., Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas, NEUROSURGER, 44(2), 1999, pp. 270-278